{"id":"cefazolin-gentamicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1200523","moleculeType":"Small molecule","molecularWeight":"476.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin is a first-generation cephalosporin that binds penicillin-binding proteins and disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Gentamicin is an aminoglycoside that binds the 30S ribosomal subunit, inhibiting protein synthesis and causing bactericidal effects. Together, they provide enhanced coverage against gram-positive cocci and some gram-negative organisms, commonly used for surgical prophylaxis and serious infections.","oneSentence":"This combination uses a beta-lactam antibiotic (cefazolin) to inhibit bacterial cell wall synthesis and an aminoglycoside (gentamicin) to inhibit bacterial protein synthesis, providing synergistic broad-spectrum bactericidal activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:11.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis"},{"name":"Serious gram-positive and gram-negative bacterial infections"},{"name":"Endocarditis prophylaxis in high-risk patients"}]},"trialDetails":[{"nctId":"NCT07478874","phase":"NA","title":"Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-07-01","conditions":"Surgical Site Infection (SSI)","enrollment":284},{"nctId":"NCT04731025","phase":"PHASE3","title":"Local Antibiotics for Breast Implants","status":"RECRUITING","sponsor":"Mikkel Herly","startDate":"2021-01-27","conditions":"Implant Complication, Implant Infection, Implant Site Infection","enrollment":1003},{"nctId":"NCT03283878","phase":"PHASE4","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-24","conditions":"Arthropathy of Knee, Antibiotic Prophylaxis","enrollment":1770},{"nctId":"NCT06814223","phase":"PHASE4","title":"Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-10-28","conditions":"Infection Catheter-Related","enrollment":200},{"nctId":"NCT04921436","phase":"NA","title":"Modulation of Microbiota Metabolism in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2021-10-03","conditions":"Multiple Organ Dysfunction","enrollment":60},{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":"Pancreatic Cancer","enrollment":344},{"nctId":"NCT01785641","phase":"NA","title":"Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2012-12","conditions":"Peritonitis","enrollment":300},{"nctId":"NCT05971537","phase":"PHASE4","title":"Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","status":"RECRUITING","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2023-06-15","conditions":"Peritoneal Dialysis-associated Peritonitis","enrollment":46},{"nctId":"NCT02579161","phase":"PHASE3","title":"Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2014-09","conditions":"Kidney Stones","enrollment":98},{"nctId":"NCT02395614","phase":"NA","title":"Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-12","conditions":"Breast Cancer","enrollment":88},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT03560232","phase":"PHASE4","title":"Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens","status":"TERMINATED","sponsor":"Mercy Health Ohio","startDate":"2018-07-09","conditions":"Open Fracture, Post-Op Wound Infection","enrollment":17},{"nctId":"NCT01318590","phase":"PHASE3","title":"Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis","status":"TERMINATED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2011-11-18","conditions":"Pancreatitis, Chronic","enrollment":2},{"nctId":"NCT03213249","phase":"PHASE1","title":"Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-07-25","conditions":"Breast Implant Infection, Mammoplasty","enrollment":19},{"nctId":"NCT01273818","phase":"PHASE4","title":"Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair","status":"COMPLETED","sponsor":"Diskapi Teaching and Research Hospital","startDate":"2011-01","conditions":"Inguinal Hernia","enrollment":276},{"nctId":"NCT01349738","phase":"","title":"Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants","status":"UNKNOWN","sponsor":"Rice, James C., M.D.","startDate":"2011-05","conditions":"Bacteriuria, Urinary Tract Infections, Asymptomatic Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ancef + Garamycin"],"phase":"marketed","status":"active","brandName":"Cefazolin + Gentamicin","genericName":"Cefazolin + Gentamicin","companyName":"Mercy Health Ohio","companyId":"mercy-health-ohio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a beta-lactam antibiotic (cefazolin) to inhibit bacterial cell wall synthesis and an aminoglycoside (gentamicin) to inhibit bacterial protein synthesis, providing synergistic broad-spectrum bactericidal activity. Used for Surgical site infection prophylaxis, Serious gram-positive and gram-negative bacterial infections, Endocarditis prophylaxis in high-risk patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}